AstraZeneca’s Calquence granted FDA Priority Review for untreated MCL
AstraZeneca’s sNDA submission is based on results from the Phase 3 ECHO study, which showed that Calquence combination reduced the risk of disease progression or death by 27% compared to...
Effects of interstate armed conflicts on the pharmaceutical industry
Unveiling the impact of misinformation and disinformation in the pharmaceutical industry
The ripple effects of inflation on the pharmaceutical industry
Extreme weather events: The implications for the pharmaceutical industry